secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001213900-26-025459
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Citius Pharmaceuticals reports positive Phase 1 topline results for LYMPHIR/pembrolizumab combo in gynecologic cancers
--------------------------------------------------------------------------------

- Phase 1 trial of LYMPHIR plus KEYTRUDA in 25 evaluable patients with relapsed/refractory gynecologic cancers showed 24% objective response rate and 48% clinical benefit rate.
- No unexpected safety signals or serious immune-related adverse events were observed at any dose level in the University of Pittsburgh-led study.
- Full safety and efficacy results expected to be presented at an international cancer conference later this year.
- Study investigators highlight potential for LYMPHIR to augment immune checkpoint inhibitor efficacy in ovarian cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390026025459/0001213900-26-025459-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390026025459/ea0280664-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-025459

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer